|
Analysis model
|
Study groups
|
n
|
Random-effect model
|
Fixed-effect model
|
Heterogeneity
|
|---|
|
OR (95% CI)
|
OR (95% CI)
|
χ
2
|
P
|
|---|
|
C vs. T
|
Total analysis
|
12
|
1.25 (1.04 to 1.51)
|
1.23 (1.11 to 1.37)
|
33.46
|
0.000
|
| |
PB
|
6
|
1.22 (1.05 to 1.42)
|
1.22 (1.05 to 1.42)
|
1.49
|
0.914
|
| |
HB
|
6
|
1.30 (0.90 to 1.90)
|
1.25 (1.08 to 1.44)
|
31.93
|
0.000
|
| |
ESCC
|
9
|
1.18 (1.00 to 1.39)
|
1.17 (1.04 to 1.32)
|
14.48
|
0.070
|
| |
South China
|
3
|
0.93 (0.76 to 1.14)
|
0.93 (0.76 to 1.14)
|
0.71
|
0.702
|
| |
North China
|
9
|
1.38 (1.12 to 1.70)
|
1.37 (1.21 to 1.55)
|
22.21
|
0.005
|
|
CC vs. TT
|
Total analysis
|
12
|
1.42 (0.99 to 2.04)
|
1.42 (1.15 to 1.75)
|
29.24
|
0.002
|
| |
PB
|
6
|
1.38 (1.02 to 1.88)
|
1.38 (1.02 to 1.88)
|
0.45
|
0.994
|
| |
HB
|
6
|
1.46 (0.70 to 3.04)
|
1.45 (1.09 to 1.93)
|
28.75
|
0.000
|
| |
ESCC
|
9
|
1.29 (0.94 to 1.77)
|
1.27 (1.00 to 1.62)
|
12.34
|
0.137
|
| |
South China
|
3
|
0.82 (0.54 to 1.25)
|
0.82 (0.54 to 1.24)
|
1.26
|
0.531
|
| |
North China
|
9
|
1.72 (1.16 to 2.56)
|
1.73 (1.35 to 2.22)
|
18.97
|
0.015
|
|
CC vs. CT
|
Total analysis
|
12
|
1.09 (0.89 to 1.33)
|
1.09 (0.89 to 1.32)
|
10.90
|
0.452
|
| |
PB
|
6
|
1.07 (0.80 to 1.43)
|
1.06 (0.80 to 1.42)
|
2.93
|
0.711
|
| |
HB
|
6
|
1.12 (0.78 to 1.59)
|
1.11 (0.85 to 1.45)
|
7.94
|
0.160
|
| |
ESCC
|
9
|
1.01 (0.80 to 1.28)
|
1.01 (0.80 to 1.28)
|
7.91
|
0.442
|
| |
South China
|
3
|
0.80 (0.53 to 1.21)
|
0.80 (0.53 to 1.21)
|
1.53
|
0.464
|
| |
North China
|
9
|
1.19 (0.95 to 1.50)
|
1.19 (0.95 to 1.50)
|
6.63
|
0.577
|
|
CC + CT vs. TT
|
Total analysis
|
12
|
1.35 (1.06 to 1.72)
|
1.37 (1.17 to 1.59)
|
26.54
|
0.005
|
| |
PB
|
6
|
1.36 (1.10 to 1.69)
|
1.36 (1.10 to 1.69)
|
4.10
|
0.536
|
| |
HB
|
6
|
1.39 (0.86 to 2.23)
|
1.37 (1.11 to 1.70)
|
22.44
|
0.000
|
| |
ESCC
|
9
|
1.28 (1.04 to 1.59)
|
1.28 (1.08 to 1.52)
|
11.73
|
0.164
|
| |
South China
|
3
|
0.97 (0.73 to 1.28)
|
0.97 (0.73 to 1.28)
|
0.11
|
0.947
|
| |
North China
|
9
|
1.52 (1.14 to 2.02)
|
1.58 (1.32 to 1.89)
|
18.30
|
0.019
|
|
CC vs. TT + CT
|
Total analysis
|
13
|
1.35 (1.03 to 1.76)
|
1.34 (1.13 to 1.59)
|
26.94
|
0.008
|
| |
PB
|
7
|
1.41 (1.06 to 1.89)
|
1.43 (1.13 to 1.81)
|
8.26
|
0.219
|
| |
HB
|
6
|
1.30 (0.79 to 2.14)
|
1.25 (0.98 to 1.60)
|
18.16
|
0.003
|
| |
ESCC
|
9
|
1.14 (0.88 to 1.47)
|
1.12 (0.90 to 1.40)
|
10.22
|
0.250
|
| |
South China
|
3
|
0.82 (0.56 to 1.20)
|
0.81 (0.56 to 1.19)
|
1.63
|
0.443
|
| |
North China
|
10
|
1.55 (1.17 to 2.06)
|
1.53 (1.26 to 1.86)
|
17.20
|
0.046
|
- PB population-based, HB hospital-based, ESCC esophageal squamous cell carcinoma, South China including Taiwan, Jiangsu, and Guangxi; North China including Shaxi, Xinjiang, Gansu, Ningxia, Shandong, and Henan.
